

STEP activator

BI-0314

Table of contents

Summary	2
Chemical Structure.....	2
Highlights.....	3
Target information.....	3
<i>In vitro</i> activity.....	4
<i>In vitro</i> DMPK and CMC parameters	5
<i>In vivo</i> DMPK parameters.....	5
<i>In vivo</i> pharmacology	5
Negative control.....	5
Selectivity.....	5
Co-crystal structure of the Boehringer Ingelheim probe compound and the target protein.....	6
Reference molecule(s).....	6
Supplementary data	6
References.....	6

Summary

BI-0314 is the first allosteric activator for STEP (PTPN5). The compound may be used as starting point for the development of selective STEP activators.

Chemical Structure




Figure 1: 2D structure of BI-0314, a STEP activator




Figure 2: BI-0314, 3D conformation, as observed in complex with STEP (PDB code: 6H8S)

Highlights

BI-0314 is the first allosteric modulator for STEP (STriatal-Enriched Protein Tyrosine Phosphatase). It binds to the active phosphatase domain and upregulates its catalytic activity. Its activity has been demonstrated in enzymatic assays showing an activation of STEP of ~60% at 500 μ M using different readouts. The selectivity of BI-0314 was tested against the tyrosine phosphatases PTP1B and TCPTP and no signs of activation were observed at concentrations up to 500 μ M.

Target information

STEP is a multi-domain tryrosine phosphatase which exists as two splice variants, the membrane anchored longer isoform STEP61 and the cytosolic STEP46. Both isoforms share the identical kinase interaction motif (KIM) and the protein tyrosine phosphatase (PTP) domain with the phosphatase consensus motif C(X)₅R. The KIM domain mediates binding to various target kinases with high affinity, while the PTP domain catalyzes their subsequent dephosphorylation. To avoid developing ligands which potentially suffer from substrate specificity, we preferred targeting the PTP domain over the KIM domain. The PTP domain bears various conserved structural motifs, such as the WPD loop, which is crucial for the catalytic step, as its aspartate (D461) mediates proton transfer to the phosphate leaving group.

To elucidate the mode of action, an X-ray structure with BI-0314 bound STEP has been solved demonstrating remote site binding ~20 Å away from the active phosphatase site. The allosteric binding site could be confirmed also in solution by 15N TROSY NMR. Long range allosteric mechanisms have been confirmed by extensive molecular dynamics simulations. The identification of a druggable allosteric pocket provides new opportunities for the discovery of selective STEP modulators.




Figure 3: STEP structure and allosteric binding site with bound ligand (orange sticks), PDB code: 6H8S.

In vitro activity

BI-0314 displays an activation of STEP of ~60% at 500µM on the dephosphorylation of a pFYN derived peptide.

PROBE NAME			BI-0314
MW [Da, free base] ^a			286.3
Enzyme	Substrate	Assay technology	Effect of BI-0134 in assay
hSTEP46 ^b	pFYN-peptide	RapidFire (MS)	Activating 56% ± 5 % at 500 µM, (n=8) 33% ± 12 % at 100 µM, (n=12)
hSTEP46 ^b	pFYN-peptide	AlphaLISA	Activating 28% ± 5 % at 100 µM, (n=4)
PTP domain of hSTEP ^b	pFYN-peptide	AlphaLISA	Activating 61% ± 6% at 500 µM, (n=10)

hSTEP46 ^b	DiFMUP	Fluorescence	Activating 48% ± 8 % at 1000 µM, (n=3) 27% ± 5 % at 300 µM, (n=3)
----------------------	--------	--------------	---

^a For the salt form you will get, please refer to the label on the vial and for the molecular weight of the salt, please refer to the FAQs

^b For detailed assay conditions see Ref. 3

***In vitro* DMPK and CMC parameters**

Not available.

***In vivo* DMPK parameters**

Not available.

***In vivo* pharmacology**

Not available.

Negative control

Not available.

Selectivity

The phylogenetically closest enzyme (TCPTP) and the “generic” tyrosine phosphatase PTP1B have been investigated and at concentrations up to 500µM of BI-0314 no signs of activation could be observed. No other panels have been tested.

SELECTIVITY DATA AVAILABLE	BI-0314
SafetyScreen44™ with kind support of  eurofins	Yes
Invitrogen®	No
DiscoverX®	No
Dundee	No

Co-crystal structure of the Boehringer Ingelheim probe compound and the target protein.

The X-ray crystal structure of target in complex with BI-0314 is available (PDB code: 6H8S).

Reference molecule(s)

No other STEP *activators* are described so far. However, there are quite potent orthosteric inhibitors described, which only show moderate selectivity over other phosphatases. (Xu 2014¹, Witten 2017²)

Supplementary data

Selectivity data can be downloaded free of charge from [openMe](#).

References

1. Xu J., Chatterjee M., Baguley T. D., Brouillette J., Kurup P., Ghosh D., Kanyo J., Zhang Y., Seyb K., Ononenyi C., Foscue E., Anderson G. M., Gresack J., Cuny G. D., Glicksman M. A., Greengard P., Lam T. T., Tautz L., Nairn A. C., Ellman J. A., Lombroso P. J. Inhibitor of the tyrosine phosphatase STEP reverses cognitive deficits in a mouse model of Alzheimer's disease *PLoS Biol* **2014**, 12(8), e1001923. [DOI: 10.1371/journal.pbio.1001923](#), [PubMed: 25093460](#).
2. Witten M. R., Wissler L., Snow M., Geschwindner S., Read J. A., Brandon N. J., Nairn A. C., Lombroso P. J., Käck H., Ellman J. A. X-ray Characterization and Structure-Based Optimization of Striatal-Enriched Protein Tyrosine Phosphatase Inhibitors *J Med Chem* **2017**, 60(22), 9299–9319. [DOI: 10.1021/acs.jmedchem.7b01292](#), [PubMed: 29116812](#).
3. Tautermann C. S., Binder F., Büttner F. H., Eickmeier C., Fiegen D., Gross U., Grundl M. A., Heilker R., Hobson S., Hoerer S., Luippold A., Mack V., Montel F., Peters S., Bhattacharya S., Vaidehi N., Schnapp G., Thamm S., Zeeb M. Allosteric Activation of Striatal-Enriched Protein Tyrosine Phosphatase (STEP, PTPN5) by a Fragment-like Molecule *J Med Chem* **2019**, 62(1), 306–316. [DOI: 10.1021/acs.jmedchem.8b00857](#), [PubMed: 30207464](#).
4. Goebel-Goody S. M., Baum M., Paspalas C. D., Fernandez S. M., Carty N. C., Kurup P., Lombroso P. J. Therapeutic implications for striatal-enriched protein tyrosine

phosphatase (STEP) in neuropsychiatric disorders *Pharmacol Rev* **2012**, 64(1), 65–87. DOI: [10.1124/pr.110.003053](https://doi.org/10.1124/pr.110.003053), PubMed: [22090472](https://pubmed.ncbi.nlm.nih.gov/22090472/).

5. Zhang Y., Kurup P., Xu J., Carty N., Fernandez S. M., Nygaard H. B., Pittenger C., Greengard P., Strittmatter S. M., Nairn A. C., Lombroso P. J. Genetic reduction of striatal-enriched tyrosine phosphatase (STEP) reverses cognitive and cellular deficits in an Alzheimer's disease mouse model *Proc Natl Acad Sci U S A* **2010**, 107(44), 19014–19019. DOI: [10.1073/pnas.1013543107](https://doi.org/10.1073/pnas.1013543107), PubMed: [20956308](https://pubmed.ncbi.nlm.nih.gov/20956308/).
6. Kurup P. K., Xu J., Videira R. A., Ononenyi C., Baltazar G., Lombroso P. J., Nairn A. C. Step61 is a substrate of the E3 ligase parkin and is upregulated in Parkinson's disease *Proc Natl Acad Sci U S A* **2015**, 112(4), 1202–1207. DOI: [10.1073/pnas.1417423112](https://doi.org/10.1073/pnas.1417423112), PubMed: [25583483](https://pubmed.ncbi.nlm.nih.gov/25583483/).
7. Carty N. C., Xu J., Kurup P., Brouillette J., Goebel-Goody S. M., Austin D. R., Yuan P., Chen G., Correa P. R., Haroutunian V., Pittenger C., Lombroso P. J. The tyrosine phosphatase STEP: Implications in schizophrenia and the molecular mechanism underlying antipsychotic medications *Transl Psychiatry* **2012**, 2(7), e137. DOI: [10.1038/tp.2012.63](https://doi.org/10.1038/tp.2012.63), PubMed: [22781170](https://pubmed.ncbi.nlm.nih.gov/22781170/).